GENZYME - THE KING OF THE BIOTECHS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aliveinsf who wrote (316)	7/29/1998 3:47:00 PM
From: Caveat Emptor	Read Replies (1) of 410

Atragen - Tretinoin Information.... A venture fund OAK INVESTMENT PARTNERS (et al) has funded both Genzyme and Aronex for many years. Both companies are identified as "Portfolio Companies" at the OAK web site. oakinv.com The ATRAGEN drug, and its collaboration with Genzyme is identified in the ARONEX Filings. But OAK Partners identify the drug.... "The company (Aronex) has a collaboration with Genzyme Corporation to develop TRETINOIN for the treatment of KAPOSI's Sarcoma and Acute Promyelocytic Leukemia"... I am confused. Is the Collaboration still active, and what drug is involved? Are these the same drug, and why are they identified by 2 seperate names? CAVEAT EMPTOR

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next